iRhythm Holdings Inc Dossier
|
SectorHealth Care IndustryMedical Devices Beta (adjusted)1.21 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $113.66Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $3.7B Enterprise Value $4.2B Shares Outstanding 32.9M diluted Moat Rating None Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary iRhythm Technologies is a leading digital healthcare company disrupting the ambulatory cardiac monitoring market with its Zio platform. Despite near-term headwinds from regulatory delays of its next-generation Zio MCT device and legal overhangs, the company's core business remains highly robust. This is demonstrated by a 25.7% year-over-year revenue increase in Q1 2026 to $199.4 million, driven by strong volume demand. Furthermore, iRhythm is successfully executing on operational efficiencies, expanding its gross margin to 70.9% and significantly narrowing its GAAP net loss. With raised full-year 2026 guidance and a massive underpenetrated global addressable market, the current valuation gap presents a compelling entry point for long-term investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$157.00 Mean target$176.86 High · most bullish analyst$200.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $115.0015% The bear case reflects prolonged regulatory delays for Zio MCT beyond 2027, intensifying competition from traditional medical device giants and digital health entrants, and substantial legal settlements or penalties stemming from the ongoing DOJ subpoena and shareholder investigations. Base CaseCentral scenario $176.8660% Matches the consensus meanThe base case is built on iRhythm achieving its raised full-year 2026 revenue guidance of $875 million to $885 million (representing 17% to 18% growth) and adjusted EBITDA margins of 12% to 13%. It assumes steady core volume growth of Zio Monitor and Zio AT, with the Zio MCT launch successfully executing in 2027. Bull CaseUpside scenario $255.0025% The bull case assumes rapid market penetration in primary care and international markets, alongside swift FDA approval of the next-generation Zio MCT device. This scenario projects accelerated revenue growth exceeding 20% annually, with adjusted EBITDA margins expanding past 15% as manufacturing automation and scale benefits maximize operating leverage. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |